Form 4: VYNE Therapeutics CFO Tyler Zeronda Reports Stock Transaction
SEC Form 4 Filing
Tyler Zeronda, CFO of VYNE Therapeutics, reports the disposal of 92 common stock shares to cover tax obligations related to vesting restricted stock units on July 1, 2024.
Summary
- On July 1, 2024, Tyler Zeronda, the Chief Financial Officer of VYNE Therapeutics Inc., disposed of 92 shares of common stock.
- The transaction was executed to cover tax withholding requirements associated with the vesting of restricted stock units.
- The price per share was $1.92.
- Following the transaction, Zeronda directly owns 131,651 shares of VYNE Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine transaction related to tax obligations on vested stock, and doesn't indicate a significant change in the company's financial health or management's confidence.
Industry Context
This is a routine Form 4 filing, indicating a transaction by a company insider. Such filings are common and provide transparency into the trading activities of company executives and directors. It is a normal part of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 07/01/2024 | Date of the stock transaction where 92 shares were disposed of to cover tax obligations. |
| 07/03/2024 | Date of signature by Attorney-in-Fact Mutya Harsch. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.